|

Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue

RECRUITINGN/ASponsored by Charite University, Berlin, Germany
Actively Recruiting
PhaseN/A
SponsorCharite University, Berlin, Germany
Started2026-03-02
Est. completion2028-03
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07438964

Summary

The neurobiological basis of central fatigue in multiple sclerosis remained unclear so far. This study investigates reward-related brain mechanisms, inflammation, and their modulation by non-invasive brain stimulation using fMRI, proteomics, and clinical measures to improve future treatment of central fatigue in MS. In the study, persons suffering from relapsing-remitting MS (RRMS) with vs. without comorbid central fatigue will be included. The study comprises five experimental visits conducted at Charité University Medicine on five consecutive days (i.e., V1 - V5) and two follow-up visits two (V6) and four (V7) weeks after V5. True or sham anodal transcranial Direct Current Stimulation (tDCS) is applied to the left dorsolateral prefrontal cortex (dlPFC) at the five visits V1 to V5. All primary and secondary outcomes are assessed at V1 and V5. At V6 and V7, measures of central fatigue are additionally assessed via questionnaires which are send to and back from the patients via mail. Participants of all groups will participate in all visits.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Men and women

  * 18 - 70 years
  * Established MS diagnosis (relapsing-remitting MS; RRMS) prior to study inclusion
  * Maximal EDSS of 4
  * Maximal disease duration 10 years
  * Existing health insurance
  * Stable or no treatment with disease modifying treatment (DMT) in last six months prior to study onset
  * Persons with RRMS and FSMC score ≥ 22 will be included in group "RRMS with fatigue"
  * Persons with RRMS and FSMC score \< 22 will be included in group "RRMS without fatigue"

Exclusion Criteria:

* • MRI contraindications

  * Known endocrine, immunologic, psychiatric, and neurologic disease (other than RRMS and Major Depressive Diosorder)
  * Current treatment with pharmaceuticals affecting monoaminergic functioning such as Levodopa, Amantadin, Fluoxetin, Paroxetin or antipsychotics
  * Relapse or treatment with steroids in last four weeks window prior to study onset
  * DMT other than B-cell depleting monoclonal antibodies or fumarates
  * Sleep disorder as assessed with Pittsburgh Sleep Quality Index

Conditions2

Fatigue in Multiple SclerosisMultiple Sclerosis

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.